Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation

British Journal of Haematology

Volumn 123, Issue 4, 2003, Pages 662-670

  Junghanss, Christian ^a,c   Storb, Rainer ^a,b   Maris, Michael B ^a,b   Carter, Rachel A ^a   Sandmaier, Brenda M ^a,b   Maloney, David G ^a,b   McSweeney, Peter A ^a,b,d   Corey, Lawrence ^a,b   Boeckh, Michael ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytomegalovirus; Infection; Non myeloablative stem cell transplantation; Related; Unrelated

Indexed keywords

ANTIVIRUS AGENT; FLUDARABINE;

ADULT; ARTICLE; CANCER SURVIVAL; CATHETER ABLATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INCIDENCE; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; SERODIAGNOSIS; VIREMIA; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; VIREMIA;

EID: 0345392525     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04671.x     Document Type: Article

References (33)

1. Bainton, R.D., Byrne, J.L., Davy, B.J. & Russell, N.H. (2002) CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood, 100, 3843-3844.
2. Boeckh, M. (1999) Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transplant Infectious Disease, 1, 165-178.
3. Boeckh, M. & Marr, K. (2002) Infections in hematopoietic stem cell transplantation. In: Clinical Approach to Infection in the Compromised Host (ed. by R. Rubin & L.S. Young). pp. 527-572. Plenum Medical Book Company, New York.
4. Boeckh, M., Gooley, T.A., Myerson, D., Cunningham, T., Schoch, G. & Bowden, R.A. (1996) Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88, 4063-4071.
5. Boeckh, M., Bowden, R.A., Gooley, T., Myerson, D. & Corey, L. (1999) Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood, 93, 1781-1782.
6. Boeckh, M., Leisenring, W., Riddell, S.R., Bowden, R.A., Huang, M.L., Myerson, D., Stevens-Ayers, T., Flowers, M.E., Cunningham, T. & Corey, L. (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood, 101, 407-414.
7. Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 4357-4363.
8. Childs, R.W., Clave, E., Tisdale, J., Plante, M., Hensel, N. & Barrett, J. (1999) Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. Journal of Clinical Oncology, 17, 2044-2049.
9. Einsele, H., Ehninger, G., Hebart, H., Wittkowski, K.M., Schuler, U., Jahn, G., Mackes, P., Herter, M., Klingebiel, T. & Loffler, J. (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood, 86, 2815-2820.
10. Feinstein, L., Sandmaier, B., Maloney, D., McSweeney, P.A., Maris, M., Flowers, C., Radich, J., Little, M.T., Nash, R.A., Chauncey, T., Woolfrey, A., Georges, G., Kiem, H.P., Zaucha, J.M., Blume, K.G., Shizuru, J., Niederwieser, D. & Storb, R. (2001) Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Annals of New York Academy of Science, 938, 328-337.
11. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H. & Champlin, R. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89, 4531-4536.
12. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295-304.
13. Husni, R.N., Gordon, S.M., Longworth, D.L., Arroliga, A., Stillwell, P.C., Avery, R.K., Maurer, J.R., Mehta, A. & Kirby, T. (1998) Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clinical Infectious Diseases, 26, 753-755.
14. Junghanss, C., Boeckh, M., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Chauncey, T., McSweeney, P.A., Little, M.T., Corey, L. & Storb, R. (2002a) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared to myeloablative allogeneic stem cell transplantation, a matched control study. Blood, 99, 1978-1985.
15. Junghanss, C., Marr, K.A., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Chauncey, T., McSweeney, P.A. & Storb, R. (2002b) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study, Biology of Blood and Marrow Transplantation, 8, 512-520.
16. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., de Elvira. M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. & Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 96, 2419-2425.
17. Ljungman, P. (1998) Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplantation, 21 (Suppl 2), S72-S74.
18. Ljungman, P., Oberg, G., Aschan, J., Ehrnst, A., Lonnqvist, B., Pauksen, K. & Sulila, P. (1996) Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplantation, 18, 565-568.
19. Ljungman, P., Aschan, J., Lewensohn-Fuchs, I., Carlens, S., Larsson, K., Lonnqvist, B., Mattsson, J., Sparrelid, E., Winiarski, J. & Ringden, O. (1998) Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation, 66, 1330-1334.
20. Ljungman, P., Griffiths, P. & Paya, C. (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clinical Infectious Diseases, 34, 1094-1097.
21. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-3400.
22. Maris, M., Woolfrey, A., McSweeney, P.A., Sandmaier, B.M., Nash, R.A., Georges, G., Maloney, D.G., Molina, A., Chauncey, T., Yu, C., Zaucha, J.M., Blume, K.G., Shizuru, J., Niederwieser, D. & Storb, R. (2001) Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. Frontiers in Bioscience, 6, G13-G16.
23. Marr, K.A., Seidel, K., Slavin, M.A., Bowden, R.A., Schoch, H.G., Flowers, M.E., Corey, L. & Boeckh, M. (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, 96, 2055-2061.
24. Martino, R., Caballero, M.D., Canals, C., San Miguel, J., Sierra, J., Rovira, M., Solano, C., Bargay, J., Perez-Simon, J., Leon, A., Sarra, J., Brunet, S. & De La, C.R. (2001a) Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 28, 341-347.
25. Martino, R., Caballero, M.D., Canals, C., Simon, J.A., Solano, C., Urbano-Ispizua, A., Bargay, J., Rayon, C., Leon, A., Sarra, J., Odriozola, J., Conde, J.G., Sierra, J. & San Miguel, J. (2001b) Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multi-centre study. British Journal of Haematology, 115, 653-659.
26. Niederwieser, D., Maris, M., Shizuru, J.A., Petersdorf, E., Hegenbart, U., Sandmaier, B.M., Maloney, D.G., Storer, B., Lange, T., Chauncey, T., Deininger, M., Poenisch, W., Anasetti, C., Woolfrey, A., Little, M.T., Blume, K.G., McSweeney, P.A. & Storb, R.F. (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 101, 1620-1629.
27. Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. & Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 3121-3127.
28. Petersdorf, E.W., Gooley, T.A., Anasetti, C., Martin, P.J., Smith, A.G., Mickelson, E.M., Woolfrey, A.E. & Hansen, J.A. (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood, 92, 3515-3520.
29. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
30. Small, T.N., Papadopoulos, E.B., Boulad, F., Black, P., Castro-Malaspina, H., Childs, B.H., Collins, N., Gillio, A., George, D., Jakubowski, A., Heller, G., Fazzari, M., Kernan, N., Mackinnon, S., Szabolcs, P., Young, J.W. & O'Reilly, R.J. (1999) Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood, 93, 467-480.
31. Souza, J.P., Boeckh, M., Gooley, T.A., Flowers, M.E. & Crawford, S.W. (1999) High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clinical Infectious Diseases, 29, 1467-1471.
32. Sykes, M., Preffer, F., McAfee, S., Saidman, S.L., Weymouth, D., Andrews, D.M., Colby, C., Sackstein, R., Sachs, D.H. & Spitzer, T.R. (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet, 353, 1755-1759.
33. Zaia, J.A., Gallez-Hawkins, G.M., Tegtmeier, B.R., ter Veer, A., Li, X., Niland, J.C. & Forman, S.J. (1997) Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. Journal of Infectious Diseases, 176, 782-785.